Skip to content

Comparing different doses of dexmedetomidine in attenuating extubation response in controlled hypertensive patients for surgeries under general anaesthesia

A study for evaluating different doses of dexmedetomidine in attenuating extubation response in controlled hypertensive patients for surgeries under general anaesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009486
Enrollment
90
Registered
2017-08-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- controlled hypertensive patients undergoing surgery under general anesthesia Health Condition 2: I10- Essential (primary) hypertension

Interventions

Intervention1: intravenous dexmedetomidine: intavenous dexmedetomidine in doses of 0.5mcg/kg,0.75mcg/kg and 1.0mcg/kg Control Intervention1: intravenous dexmedetomidine comapared in three doses: comap

Sponsors

Dr Rajendra Prasad Government Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Controlled hypertensive patients on antihypertensive drugs for surgery under general anaesthesia 2. American society of Anesthesiologist physical status II 3. Body Mass Index is under 30 Kg/m2

Exclusion criteria

Exclusion criteria: 1. Untreated hypertension 2. Users of ACE inhibitors as antihypertensive therapy 3. History of severe cardiovascular disease, renal disease, diabetes mellitus, cerebrovascular disease. 4. Known hypersensitivity to the drug. 5. Difficult airway 6. Any patient who receives blood transfusion. 7. Patients refusal for participation in the study. 8.Patients with ischaemic and/or congestive cardiac disease or abnormal electrocardiography. 9. Patients on digoxin, anticonvulsant or psychotropic medicines. 10. If bradycardia (heart rate 11. If bispectral index (BIS) > 60 anytime between starting of infusion and extubation, patient to be excluded from the study. 12. If systolic blood pressure >180 mm of Hg during study period. 13.If surgery is not completed within 10 mintues of starting infusion.

Design outcomes

Primary

MeasureTime frame
a study for evaluating different doses of dexmedetomidine in attenuating extubation response in controlled hypertensive patients for surgeries under general anaesthesia. Timepoint: hemodynamic response every 30 seconds till 5 min and thereafter every 15 min till 2 hours.

Secondary

MeasureTime frame
.Pulse rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), oxygen saturation (SpO2) and bispectral index (BIS) .Extubation time will be noted and extubation quality .Sedation will be evaluated using Ramsay Sedation Scale .Any side effects in form of postoperative nausea, vomiting and bradycardiaTimepoint: extubation quality for a period of 15 min post extubation, sedation 5 minute interval uptill 30 min and thereafter at 30 min interval for next 90 minutes and side effects

Countries

India

Contacts

Public ContactDr Sudarshan Kumar

DR RPGMC Kangra at Tanda,HPU

sudarshan_58@rediffmail.com9418086604

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026